Yahoo · Nov 4, 2026
Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Robert Wenham, M.D., Chair of the Gynecologic Oncology Program at Moffitt Cancer Center ("Moffitt") and principal investigator of Anixa's ongoing Phase 1 clinical trial evaluating its novel CAR-T therapy for recurrent ovarian cancer, will present at the ESMO (European Society of Medical Oncology) Immuno-Oncology & Advanced Therapies Co

